"Shares Hold Significant Upside Potential" - Oppenheimer Reiterates Outperform Rating, $5 Price Target on Avalo Therapeutics (AVTX)
Tweet Send to a Friend
Oppenheimer analyst Leland Gershell reiterated an Outperform rating and $5.00 price target on Avalo Therapeutics Inc. (NASDAQ: AVTX), as the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
